beta-Lactamase Inhibitors
"beta-Lactamase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
| Descriptor ID |
D065093
|
| MeSH Number(s) |
D27.505.519.389.400 D27.505.954.122.085.516
|
| Concept/Terms |
beta-Lactamase Inhibitors- beta-Lactamase Inhibitors
- Inhibitors, beta-Lactamase
- beta Lactamase Inhibitors
- Inhibitors, beta Lactamase
- Lactamase Inhibitors, beta
- beta Lactamase Antagonists
- Antagonists, beta Lactamase
- Lactamase Antagonists, beta
|
Below are MeSH descriptors whose meaning is more general than "beta-Lactamase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "beta-Lactamase Inhibitors".
This graph shows the total number of publications written about "beta-Lactamase Inhibitors" by people in this website by year, and whether "beta-Lactamase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta-Lactamase Inhibitors" by people in Profiles.
-
Structural and biochemical analysis of the metallo-ß-lactamase L1 from emerging pathogen Stenotrophomonas maltophilia revealed the subtle but distinct di-metal scaffold for catalytic activity. Protein Sci. 2020 03; 29(3):723-743.
-
Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient. J Antimicrob Chemother. 2018 12 01; 73(12):3529-3531.
-
Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect. 2008 Jan; 14 Suppl 1:181-4.
-
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006 Jun; 50(6):2244-7.
-
ENDOR structural characterization of a catalytically competent acylenzyme reaction intermediate of wild-type TEM-1 beta-lactamase confirms glutamate-166 as the base catalyst. Biochemistry. 2001 Feb 27; 40(8):2397-409.
-
Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene. Antimicrob Agents Chemother. 1998 Jul; 42(7):1542-8.
-
Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Antimicrob Agents Chemother. 1995 Aug; 39(8):1878-80.
-
Molecular correlation between in vitro and in vivo activity of beta-lactam and beta-lactamase inhibitor combinations against methicillin-resistant Staphylococcus aureus. J Lab Clin Med. 1995 Feb; 125(2):200-11.
-
Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime. Antimicrob Agents Chemother. 1994 May; 38(5):1134-9.